Everis Medical and Hemostasis, LLC Combine to Create a Leading Independent ENT Surgical Company
Transformational combination unites Everis' Otolaryngology/Head & Neck portfolio with Hemostasis' chitosan-based sinus
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
![]()
Everis Medical (“Everis”), a medical device company specializing in Otolaryngology, Head & Neck Surgery and adjacent surgical specialties, and Hemostasis, LLC (“Hemostasis”), an innovator in advanced sinus dressings and surgical hemostats, announced that the two companies have combined. The combined organization will operate as Everis Medical, with Hemostasis’ technologies and people becoming a core part of Everis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117832818/en/
The transaction is Everis’ sixth since 2019 and is the most significant step in Everis’ history. It brings together two companies of comparable scale, and it gives the combined organization a cohesive portfolio for sinus and nasal surgery: repair and reconstruction, hemostasis, post-operative healing and infection management.
“This is a defining moment for Everis,” said Kevin McLeod, Founder and CEO, Everis Medical. “Hemostasis has built something rare: a proprietary technology platform that surgeons trust. Bringing our teams together creates a company with the scale, the portfolio and the innovation engine to lead in ENT surgery.”
“From the start, we have been driven by a simple idea: continuous improvement and innovation leads to better outcomes for patients,” said Michael Spearman, Co-Founder and Chairman, Hemostasis, LLC. “Coming together with Everis is a true joining of two companies that share the same ambition. As part of Everis, our technologies will reach more surgeons and more patients, faster, and together we will continue advancing the technology in sinus dressings.”
“Everis and Hemostasis together form a stronger company than either could build alone,” said Don Pierce, Partner at Shore Capital Partners and Chairman of the Board of Everis. “This combination is exactly the kind of transformational step our partnership with Everis was designed to support, and we look forward to investing behind the combined team’s growth.”
The combined company will operate as Everis Medical, led by Kevin McLeod as CEO. Hemostasis’ St. Paul, Minnesota facility will continue to develop and manufacture the platform. Hemostasis technologies will continue to be sold under their existing brand names as part of the Everis portfolio. Customers of both companies will experience a seamless transition, with uninterrupted access to technologies, service and support.
Piper Sandler & Co. served as financial advisor and Fox Rothschild LLP served as legal advisor to Hemostasis on the transaction. DLA Piper LLP served as legal advisor to Everis and Shore Capital, and Cain Brothers served as buy-side financial advisor to Shore Capital.
About the companies
About Everis
Everis Medical is a Kalamazoo, MI-based medical device company focused on Otolaryngology, Head & Neck Surgery, Ear, Nose & Throat, and adjacent specialty markets. Everis builds a portfolio of acquired and developed technologies to drive advancements and improve patient outcomes. Since its founding in 2019, Everis has expanded through the acquisition of the Cook Medical OHNS product line, the Shaw Scalpel, the STIC Pressure Monitor, the T/Pump Temperature Therapy System, Hood Laboratories, and Hemostasis, LLC. Backed by Shore Capital, Everis is supported by a Board of Directors with deep experience across medical device operations. For more information, visit everismedical.com.
Transaction highlights
- Operating company: Everis Medical (Kalamazoo, MI)
- Combined with: Hemostasis, LLC (St. Paul, MN) — developer of chitosan-based sinus dressings and surgical hemostats
- Structure: The combined organization operates as Everis Medical
- Significance: Everis’ sixth and largest transaction since its founding in 2019
- Technologies added: PosiSep® sinus dressings family, BAM antimicrobial technology, NexPak™ X, NexStat™ / NexStat™ Plus, NexFoam™, BleedArrest® ER, as well as other pipeline technologies
- Private equity partner: Shore Capital Partners
- Terms: Not disclosed
About Hemostasis, LLC
Hemostasis, LLC, now part of Everis Medical, develops advanced medical technologies built on its proprietary NOCC and BioNOCC chitosan polymer platforms. Its portfolio includes the PosiSep® family of hemostatic sinus dressings, BAM antimicrobial sinus dressings, and the NexPak™, NexStat™, NexFoam™ and BleedArrest® product lines. Hemostasis works with leading surgeons and key opinion leaders to create technologies that improve usability, efficacy and patient outcomes. For more information, visit hemostasisllc.com.
About Shore Capital Partners
Shore Capital, a Chicago-based private equity firm with an office in Nashville, is an investor in lower-middle market companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore’s strategy is to support management partners to grow faster with less risk through access to capital, world-class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. From 2020-2025, Shore received recognition from Inc. Magazine as a 6x Top Founder Friendly Investor and by Pitchbook Research for leading U.S. Private Equity deal volume for the past 10 years, from 2016-2025. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $17 billion of assets under management and in additional investment platforms to which it provides business and operational consulting services. To learn more about Shore Capital Partners, and for more information on these awards and investment platforms, please visit www.shorecp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261117832818/en/
Media gallery


